Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nifekalan-guided progressive ablation for persistent atrial fibrillation
ChiCTR2100054521Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of nifekalant in Atrial fibrillation (AFib) (2 arms), sponsored by The Second Affiliated Hospital of Nanchang University. Primary endpoint: Atrial fibrillation recurrence at 6 months. Started Nov 2021; status: recruiting.
02
Drugs
nifekalant
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ChiCTR2100054521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054521.